Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OT-C001 in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
NCT07044050Phase 1Recruiting
- Sponsor
- Emercell
- Start
- Jun 2025
- Primary completion
- Sep 2026
- Modality
- Lymphokine-Activated Killer Cells, CAR-NK Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of OT-C001 in diffuse large B-cell lymphoma (DLBCL) (3 cohorts), sponsored by Emercell. Primary endpoint: Incidence and Severity of Treatment-Emergent Adverse Events. Started Jun 2025; status: recruiting.
02
Drugs
OT-C001
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT07044050.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07044050.